Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.
Artak LabadzhyanL B NachtigallMaria FleseriuM B GordonM MolitchL KennedySusan L SamsonYona GreenmanNienke R BiermaszMarek BolanowskiA HavivW LudlamG PatouChristian J StrasburgerPublished in: Pituitary (2021)
OOC demonstrated remarkably consistent results for biochemical response, durability of response, and preference to continue with oral treatment across these 2 complementary landmark phase 3 trials, despite differences in the design of each. Trial registration NCT03252353 (August 2017), NCT01412424 (August 2011).